Fabhalta (iptacopan) is a complement inhibitor used to treat adults with a rare blood condition called paroxysmal nocturnal hemoglobinuria (PNH). It also helps to reduce protein levels in the urine for certain people with a kidney condition called primary immunoglobulin A nephropathy (IgAN). This medication comes as a capsule that you take by mouth twice a day. Common side effects include headache, diarrhea, and stomach pain. Fabhalta (iptacopan) is only available through a special Risk Evaluation and Mitigation Strategies (REMS) program since it raises the risk for serious infections.
Fabhalta (iptacopan) is a complement inhibitor. It works by blocking a part of the immune system called the alternative complement pathway. This helps control a chain of immune reactions that can lead to damage in certain conditions.
In PNH, the immune system attacks red blood cells leading to their destruction. Fabhalta (iptacopan) helps protect these cells by blocking the complement system early in the process, reducing symptoms of PNH.
In IgAN, certain immune proteins build up in the kidneys and cause inflammation, which can lead to kidney damage over time. By blocking the alternative complement pathway, Fabhalta (iptacopan) has been shown to reduce protein levels in the urine, potentially protecting the kidney.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
PNH:
IgAN:
PNH:
IgAN:
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Yes. Fabhalta (iptacopan) is available in the United States, but only under a special REMS program required by the FDA since the medication raises the risk of serious infections. This means your prescriber and pharmacy must be specially trained to prescribe and dispense it. You’ll also need to enroll in the program and receive counseling on how to take the medication safely.
In clinical studies, 82% of people taking Fabhalta (iptacopan) had significantly higher hemoglobin levels, the protein in your blood that carries oxygen, after about 6 months. Additionally, 67% had hemoglobin levels above 12 g/dL without needing blood transfusions.
Fabhalta (iptacopan) is unique as it's the first oral medication for PNH. Other treatments, like Soliris (eculizumab) or Ultomiris (ravulizumab), are typically given as injections. Speak to your prescriber if you want to learn more about the differences between these medications.
It's not known if Fabhalta (iptacopan) is safe to use during pregnancy since it hasn't been studied. If you're pregnant or planning to become pregnant, talk to your prescriber to discuss the potential risks and benefits before taking this medication.
It's not known if Fabhalta (iptacopan) passes into breast milk or how it might affect a breastfed baby. To be safe, it's recommended to stop breastfeeding during treatment and for 5 days after the last dose.
Fabhalta (iptacopan) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Fabhalta (iptacopan) can weaken your body's ability to fight off infections, raising the risk for serious and life-threatening infections, like meningitis, pneumonia, and Haemophilus influenzae disease (Hib disease). Before starting Fabhalta (iptacopan), you must be up to date on vaccines. You might need the pneumonia vaccine, meningitis vaccine, and the Hib vaccine at least 2 weeks before your treatment begins. Your healthcare professional (HCP) will check if you need additional vaccines or preventive antibiotics before and during treatment. Even if you are vaccinated, you can still get serious infections. Get medical help right away if you have signs of an infection, such as fever, chills, body aches, cough, nausea, vomiting, eyes that are sensitive to light, neck pain or stiffness, severe headache, or confusion.
Because of the risk for serious infections, Fabhalta (iptacopan) is only available through a restricted Risk Evaluation and Mitigation Strategies (REMS) program called Fabhalta REMS. Your HCP must enroll in this program to prescribe it. They will also discuss infection risks with you and how to stay protected. During treatment and for 2 weeks after your last dose, you must carry a Patient Safety Card at all times in case of an emergency.
If you have PNH and stop taking Fabhalta (iptacopan), your prescriber will monitor you for at least 2 weeks for signs of hemolysis (red blood cell breakdown). Contact them if you notice tiredness, stomach pain, shortness of breath, blood in your urine, trouble swallowing, or erectile dysfunction. If signs of hemolysis appear after stopping, your prescriber might consider restarting Fabhalta (iptacopan) or switching you to a different PNH medication.
Fabhalta (iptacopan) can raise your blood cholesterol and triglyceride levels. Your prescriber will likely order regular blood tests during treatment to make sure your levels stay in a safe range. If your cholesterol gets too high, they might prescribe a cholesterol-lowering medication or consider stopping Fabhalta (iptacopan).
| Dosage | Quantity | Price as low as | Price per unit |
|---|---|---|---|
| 200mg of | 60 capsules | $0.00 | $0.00 |
The typical dose is 200 mg by mouth twice a day with or without food.
Contraindications are specific health conditions or situations in which a person should not take a medication due to safety concerns. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Fabhalta (iptacopan) will not be safe for you to take.